-
1
-
-
17144474314
-
Gene expression signatures define novel oncogenic pathways in t cell acute lymphoblastic leukemia
-
Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 75-87.
-
(2002)
Cancer Cell
, vol.1
, pp. 75-87
-
-
Ferrando, A.A.1
Neuberg, D.S.2
Staunton, J.3
Loh, M.L.4
Huard, C.5
Raimondi, S.C.6
-
2
-
-
40749150603
-
Acute lymphoblastic leukaemia
-
Pui CH, Robinson LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043.
-
(2008)
Lancet
, vol.371
, pp. 1030-1043
-
-
Pui, C.H.1
Robinson, L.L.2
Look, A.T.3
-
3
-
-
78649991073
-
Notch signaling in t cell lymphoblastic leukemia/lymphoma and other hematological malignancies
-
Aster JC, Backlow SC, Pear WS. Notch signaling in T cell lymphoblastic leukemia/lymphoma and other hematological malignancies. J Pathol 2011; 223: 262-273.
-
(2011)
J Pathol
, vol.223
, pp. 262-273
-
-
Aster, J.C.1
Backlow, S.C.2
Pear, W.S.3
-
4
-
-
8544262178
-
T cell acute lymphoblastic leukemia/lymphoma: A human cancer commonly associated with aberrant notch1 signaling
-
Pear WS, Aster JC. T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling. Curr Opin Hematol 2004; 11: 426-433.
-
(2004)
Curr Opin Hematol
, vol.11
, pp. 426-433
-
-
Pear, W.S.1
Aster, J.C.2
-
5
-
-
33745203104
-
Cutll1, a novel human t-cell lymphoma cell line with t(7;9) rearrangement, aberrant notch1 activation and high sensitivity to gamma secretase inhibitors
-
Palomero T, Barnes KC, Real PJ, Glade-Bender JL, Sulis ML, Murty VV et al. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma secretase inhibitors. Leukemia 2006; 20: 1279-1287.
-
(2006)
Leukemia
, vol.20
, pp. 1279-1287
-
-
Palomero, T.1
Barnes, K.C.2
Real, P.J.3
Glade-Bender, J.L.4
Sulis, M.L.5
Murty, V.V.6
-
6
-
-
33947214529
-
Notch signalling, gamma-secretase inhibitors and cancer therapy
-
Shi I, Wang TL. Notch signalling, gamma-secretase inhibitors and cancer therapy. Cancer Res 2007; 67: 1879-1882.
-
(2007)
Cancer Res
, vol.67
, pp. 1879-1882
-
-
Shi, I.1
Wang, T.L.2
-
7
-
-
61849100923
-
Notch is a key regulator of human t-cell acute leukemia initiating cell activity
-
Armstrong F, Brunet de la Grange P, Gerby B, Rouyez MC, Calvo J, Fontenay M et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 2009; 113: 1730-1740.
-
(2009)
Blood
, vol.113
, pp. 1730-1740
-
-
Armstrong, F.1
Brunet De La Grange, P.2
Gerby, B.3
Rouyez, M.C.4
Calvo, J.5
Fontenay, M.6
-
8
-
-
77953368267
-
Evaluation of selective gamma-secretase inhibitor pf-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design
-
Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010; 9: 1618-1628.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 1618-1628
-
-
Wei, P.1
Walls, M.2
Qiu, M.3
Ding, R.4
Denlinger, R.H.5
Wong, A.6
-
9
-
-
84863786154
-
Preclinical analysis of the ?-secretase inhibitor pf-03084014 in combination with glucocorticoids in t-cell acute lymphoblastic leukemia
-
Samon JB, Castillo-Martin M, Hadler M, Ambesi-Impiobato A, Paietta E, Racevskis J et al. Preclinical analysis of the ?-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2012; 11: 1565-1575.
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 1565-1575
-
-
Samon, J.B.1
Castillo-Martin, M.2
Hadler, M.3
Ambesi-Impiobato, A.4
Paietta, E.5
Racevskis, J.6
-
10
-
-
84866431367
-
Biomarker and pharmacologic evaluation of the gamma-secretase inhibitor pf-03084014 in breast cancer models
-
Zhang CC, Pavlicek A, Zhang Q, Lira ME, Painter CL, Yan Z et al. Biomarker and pharmacologic evaluation of the gamma-secretase inhibitor PF-03084014 in breast cancer models. Clin Cancer Res 2012; 18: 5008-5019.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 5008-5019
-
-
Zhang, C.C.1
Pavlicek, A.2
Zhang, Q.3
Lira, M.E.4
Painter, C.L.5
Yan, Z.6
-
11
-
-
35748972639
-
Notch and pi3k-Akt pathways intertwined
-
Gutierrez A, Look AT. NOTCH and PI3K-AKT pathways intertwined. Cancer Cell 2007; 12: 411-413.
-
(2007)
Cancer Cell
, vol.12
, pp. 411-413
-
-
Gutierrez, A.1
Look, A.T.2
-
12
-
-
34948908663
-
Mutational loss of pten induces resistance to notch1 inhibition in t-cell leukemia
-
Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007; 13: 1203-1210.
-
(2007)
Nat Med
, vol.13
, pp. 1203-1210
-
-
Palomero, T.1
Sulis, M.L.2
Cortina, M.3
Real, P.J.4
Barnes, K.5
Ciofani, M.6
-
13
-
-
34548592412
-
A phase i clinical trial of the notch inhibitor mk-0752 in patients with t-cell acute lymphoblastic leukemia/lymphoma (t-All) and other leukemias
-
DeAngelo DJ, Stone RM, Silverman LB, Stock W, Attar EC, Fearen I et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 2006; 24: 6585.
-
(2006)
J Clin Oncol
, vol.24
, pp. 6585
-
-
DeAngelo, D.J.1
Stone, R.M.2
Silverman, L.B.3
Stock, W.4
Attar, E.C.5
Fearen, I.6
-
14
-
-
79951516547
-
Molecular pathogenesis and targeted therapies for notch1-induced t-cell acute lymphoblastic leukemia
-
Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev 2011; 25: 83-90.
-
(2011)
Blood Rev
, vol.25
, pp. 83-90
-
-
Paganin, M.1
Ferrando, A.2
-
15
-
-
84920509474
-
A phase i, dose-finding study in patients with advanced solid malignancies of the oral ?-secretase inhibitor pf-03084014
-
Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B et al. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral ?-secretase inhibitor PF-03084014. Clin Cancer Res 2015; 21: 60-67.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 60-67
-
-
Messersmith, W.A.1
Shapiro, G.I.2
Cleary, J.M.3
Jimeno, A.4
Dasari, A.5
Huang, B.6
|